GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced that it plans to release its fourth quarter and full year 2019 financial results after market close on Thursday, March 12, 2020.
Management will hold a conference call to review the company’s fourth quarter 2019 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 877-883-0383 (US/Canada) or 412-902-6506 (International), passcode 5108232, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM Systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200304005791/en/
Senseonics Investor Contact Lynn Lewis or Philip Taylor Investor Relations 415-937-5406 investors@senseonics.com
Senseonics Media Contact: Karen Hynes Public Relations 619-206-9811 Karen.hynes@senseonics.com
Source: Senseonics Holdings, Inc.